PD-1 inhibitor and topoisomerase I inhibitor

This page covers all PD-1 inhibitor and topoisomerase I inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1 and topoisomerase I.

Targets

PD-1 and topoisomerase I

Phase 2 pipeline (1)

• CMAB009 plus Irinotecan · Shanghai Zhangjiang Biotechnology Limited Company · Oncology
  CMAB009 is a PD-1 inhibitor, and Irinotecan is a topoisomerase I inhibitor.

Patent intelligence

• pd 1 inhibitor and topoisomerase i inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates